Podcasts about new treatments

There's a care model for schizophrenia that actually works—why isn't it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind.Also discussed:The first novel schizophrenia drug in over 50 years (Cobenfy)Why clozapine is underused—and how that may finally changeThe potential of brain imaging and biomarkers in psychiatric treatmentWhat a real community mental health system looks likeWhy trust, not just treatment, is essential for recovery

TODAY ON THE ROBERT SCOTT BELL SHOW: Universe 25 Experiment, David Rasnick, Kala Mandrake, Caltha Palustris, Realtime Vax Injury Tracking, New Treatments for Measles, Gold for Groceries, Bayer Glyphosate Immunity, Real Dino-Skin Purses, Question of the Day, and MORE! https://robertscottbell.com/universe-25-experiment-david-rasnick-caltha-palustris-digital-vax-injury-tracking-new-treatments-for-measles-gold-for-groceries-bayer-seeks-glyphosate-immunity-real-dino-skin-purses-question/

TakeawaysMASH is a significant obesity-related complication.Semaglutide shows promise in treating MASH.Weight loss is crucial for improving liver health.Bariatric surgery remains the most effective treatment.The Essence trial indicates a 63% resolution of NASH.New medications are being developed for obesity treatment.Early intervention is key to preventing severe liver damage.Accessibility of medications is a major concern.Comparative studies are essential for evaluating new treatments.Future treatments may include innovative delivery methods.Chapters00:00 Introduction to MASH and Semaglutide Study04:29 Understanding Metabolic Dysfunction and Its Implications08:02 Essence Trial: Semaglutide's Impact on MASH12:58 Comparative Analysis of New Treatments for MASH17:30 The Future of Obesity Treatment and Drug AccessibilityJoin Vineyard - Dr. Spencer's online clinicSee the study

In this episode, Monique Blanchard, a Clinical Nurse Consultant in Radiation Oncology at Austin Health in Melbourne, poses a series of questions to Associate Professor Sweet Ping Ng and Dr Ee Sian Choong, Radiation Oncologists also from the Austin Radiation Oncology Centre, Melbourne. You'll learn about the significant advancements in improving imaging and radiation delivery techniques, including improvements in delivery design and stereotactic radiotherapy; how these new techniques are improving patient experiences; and the challenges and future of radiation oncology.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Title: Pfizer and BioNTech seek FDA approval for COVID-19 vaccine boosterPfizer and BioNTech have announced that they are seeking authorization from the FDA for a booster dose of their COVID-19 vaccine. The companies have presented data showing that a third dose of the vaccine can significantly increase protection against the Delta variant.##Title: Moderna to supply 100 million more doses of COVID-19 vaccine to the USModerna has reached an agreement with the US government to supply an additional 100 million doses of its COVID-19 vaccine. The company will deliver the doses by the end of the year, helping to boost vaccination efforts across the country.##Title: AstraZeneca's COVID-19 antibody treatment shows promising results in clinical trialsAstraZeneca has announced that its COVID-19 antibody treatment has shown promising results in clinical trials. The treatment, which is designed to prevent severe disease and hospitalization, could provide an important new tool in the fight against the virus.##Title: Novartis receives FDA approval for new treatment for advanced breast cancerNovartis has received FDA approval for a new treatment for advanced breast cancer. The drug, which targets a specific genetic mutation, has been shown to significantly improve progression-free survival in patients with the disease.##Title: Roche announces positive results from phase 3 trial of Alzheimer's drugRoche has announced positive results from a phase 3 trial of its Alzheimer's drug. The drug, which is designed to target the underlying cause of the disease, showed significant improvement in cognitive function and daily living activities in patients with early-stage Alzheimer's.##Title: Johnson & Johnson to invest $6.5 billion in expanding vaccine production capacityJohnson & Johnson has announced plans to invest $6.5 billion in expanding its vaccine production capacity. The company aims to increase production of its COVID-19 vaccine as well as other vaccines in its portfolio, helping to address global supply shortages.##Title: Merck receives FDA approval for new treatment for certain types of lung cancerMerck has received FDA approval for a new treatment for certain types of lung cancer. The drug, which targets a specific genetic mutation, has been shown to improve overall survival in patients with advanced disease.##Title: Gilead Sciences announces collaboration with Novartis on HIV researchGilead Sciences has announced a collaboration with Novartis on HIV research. The companies will work together to develop new treatments for HIV, with a focus on addressing drug resistance and improving outcomes for patients with the virus.## Title: Eli Lilly receives FDA approval for new treatment for migraineEli Lilly has received FDA approval for a new treatment for migraine. The drug, which is administered through an injection, has been shown to provide rapid relief from migraine symptoms and reduce the frequency of attacks in patients with the condition.

In today's episode, I was very excited to sit down with Dr. Ilana Gurevich to discuss the latest, most effective approaches to GI conditions. We explore the usage of sulfur for the gut, the role of the mitochondria in the body's overall health, treating parasites, as well as SIBO and Candida. We'll also share recommended protocols for each condition. Listen now!   

In this episode of It Happened To Me, we dive into the world of Niemann-Pick Type C (NPC), a rare genetic condition that affects fewer than 1,000 people in the United States. NPC is a progressive disorder impacting the brain, nerves, and major organs, often referred to as "childhood Alzheimer's" due to its neurological effects. Our guests bring both personal and professional expertise to the conversation: Barbara Lazarus is the mother of two adult sons (now in their 30s), who have Niemann-Pick Type C disease.  David is taking Myplyffa, through an expanded access program.  Both David and her brother Daniel have been seen at UCSF Benioff Oakland Children's Hospital in the Bay Area of California.  She is a knowledgeable patient advocate of NPC.  Dr. Caroline Hastings is a Pediatric Hematologist Oncologist and Professor of Pediatrics at UCSF Benioff Children's Hospital Oakland. In addition to her specialization in pediatric cancer and blood diseases, including a focus on tumors of the brain and spinal cord, her clinical and academic interests have focused on children and adults with rare lysosomal storage diseases. Her particular area of expertise and interest is in Niemann-Pick Type C disease, a rare debilitating genetic disease that until now has been elusive to a therapeutic intervention. She has been involved in developing new drugs and treatment strategies with the hope to improve quality of life and longevity for these patients.C. Together, they provide a comprehensive look at NPC, from its symptoms and genetic causes to the challenges of diagnosis and the hope brought by new FDA-approved treatments like Miplyffa. Topics Discussed: How Niemann-Pick Type C affects the body. Early signs, symptoms, and progression of NPC in children and adults. The genetics of NPC and its inheritance patterns. The challenges of diagnosing such a rare condition and the role of genetic counseling. Insights into the newly FDA-approved treatment, Miplyffa, and its impact on patients like Barbara's son David. The importance of specialized medical centers for NPC care and the role of advocacy and community support. Key Takeaways: NPC is caused by mutations in the NPC1 and NPC2 genes, leading to the buildup of cholesterol and lipids in cells. Early diagnosis and specialized care are crucial for managing the condition and accessing treatments. The approval of Miplyffa marks a significant milestone, offering new hope for families affected by NPC. Resources Mentioned: UCSF Benioff Oakland Children's Hospital Neurology Center National Niemann Pick Disease Foundation Information on FDA-approved treatments like Miplyffa Connect with Us: Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com.   

Welcome to the Evidence-Based Hair Podcast, hosted by dermatologist and hair loss specialist Dr. Jeff Donovan. In this episode, Dr. Donovan explores a groundbreaking study published in the journal Curious, highlighting the effectiveness of the JAK1 inhibitor, upadacitinib, in treating recalcitrant dissecting cellulitis of the scalp. Dissecting cellulitis, a challenging form of scarring alopecia, often affects males and presents with debilitating symptoms. While traditional treatments like isotretinoin and antibiotics offer relief for some, they aren't always effective. The study discusses a case where upadacitinib brought significant improvement after conventional options were exhausted. Dr. Donovan provides a comprehensive overview of the study, emphasizing the potential of JAK inhibitors as third-line treatments in managing persistent dissecting cellulitis. He also shares insights on the broader implications for future research and treatment strategies. Join Dr. Donovan next week for an analysis of a study on alopecia areata and cardiovascular comorbidities, and don't miss the annual "Top 20 of 2024" event on December 30th. For more information about the Donovan Hair Academy's programs, visit their website.     STUDY REFERENCED IN THIS EPISODE Zahidul Islam, Michelle Toker, Isha M Gandhi, Ariel Sher, Kristina Campto. Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib. Cureus . 2024 Jan 16;16(1):e52377. doi: 10.7759/cureus.52377. eCollection 2024 Jan.  

Guest: Michele Lambert, MD, MSTR New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targeting drugs aim to address the root causes of ITP and offer more personalized care for patients. Dr. Lambert, the Medical Director of the Special Coagulation Laboratory and a physician in the Division of Hematology at Children's Hospital of Philadelphia, presented on this topic at the 2024 American Society of Hematology Annual Meeting.

There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens.IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclonal antibody-based therapeutic, for peanut allergy. Designed to neutralize the most clinically important peanut allergens and epitopes, IGNX001 combats peanut allergies by blocking the allergic cascade and reducing risk of anaphylaxis.Should IGNX001 prove successful, it will provide a promising solution for peanut allergies and pave the way for IgGenix's technology to be applied to other types of food allergies and allergic diseases.Our guest on the podcast this week is Jessica Grossman, chief executive officer of IgGenix.01:14-02:51: About IgGenix02:51-06:30: About peanut allergy06:30-07:31: Are allergies on the rise?07:31-08:46: Are allergy responses similar?08:46-10:13: The problems with treating allergies10:13-13:53: Current treatments for peanut allergy13:53-15:45: The challenges of developing drugs to treat allergies15:45-16:54: Overcoming the placebo effect16:54-18:18: Are other companies working on allergy treatments?18:18-21:32: IgGenix's SEQ SIFTER platform21:32-24:20: About IgGenix's IGNX00124:20-24:42: Repeat doses24:42-26:19: Could peanut allergy sufferers eat peanuts?26:19-27:46: Can the technology be adapted to treat other allergies?27:46-28:56: Are there variations in the treatment of different allergies?28:56-29:35: Treatments for other diseases29:35-30:23: The future for people with allergiesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

It's World Antimicrobial Resistance Awareness Week (WAAW) and the theme is "Educate. Advocate. Act now". It's a yearly global campaign, raising awareness of antimicrobial resistance (AMR) and promoting ways to reduce the spread of drug-resistant infections. To mark the occasion, MTPConnect's Andrew Bowskill, Co-chair of the Australian Antimicrobial Resistance Network, AAMRNet, and Anne Harris, Managing Director of Pfizer Australia and New Zealand join host Caroline Duell to discuss new approaches to fighting superbugs. Why it needs to be tackled holistically with a ‘One Health' approach across all sectors, including the environment, animal health and agriculture. They discuss the role of vaccines as the first line of defence, and why a new subscription-style reimbursement model in Australia will help support equitable access to new treatments and restimulate investment in antibiotics R&D to meet future needs. We also find out how the recent upgrade to Pfizer's manufacturing facility in Melbourne is an important development in the fight against AMR.

Current strategies to manage Erectile dysfunction (ED) and what can be improved History of ED, including duration; understanding if it's organic or psychogenic key to treating it Relationship of ED with underlying vascular comorbidities What investigations can help diagnosis for targeted treatment Overview of treatments available, including upcoming new ones   Host: Dr David Lim | Total Time: 32 mins Facilitator: Dr David Lim, General Practitioner Expert: Dr Michael Gillman, General Practitioner Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEDT Click here to register for the next oneSee omnystudio.com/listener for privacy information.

In today's episode, Dr. Addison Killeen answers a listener's question about expanding their practice beyond routine hygiene appointments. After acquiring their office in 2021, they've seen consistent growth, but now face the challenge of maintaining a healthy patient base. Dr. Killeen shares strategies like building stronger relationships with patients to introduce aesthetic treatments, clear aligners, and reengaging those on the "watch" list. Tune in for practical advice on how to elevate your surface offerings and grow your practice. For more information about Dr. Addison Killeen, visit: www.addisonkilleen.com or interact with him on a daily basis at www.DentalSuccessNetwork.com

Dr. Philip Gold is one of the world's leading researchers of depressive illness. He is here today to discuss the correlation and body's response to depression and stress, the role of inflammation in depression and how anti-inflammatory agents can help. Research notes Depression represents a dysregulation of the brain's stress response system that we depend upon for survival - why it is so critical to address stress and tips for doing it. Dr. Gold discusses data revealing depression is a total body disease that shortens life by 7 - 10 years, and that it brings increased risk of premature onset of coronary artery disease, stroke, diabetes and osteoporosis. He also discusses a new science of gene therapy including a treatment overcoming the gene mutation that interferes with resiliency, promotes vulnerability to depression, and inhibits the capacity of antidepressants to work effectively Get his new book here: https://www.amazon.com/Breaking-Through-Depression-Generation-Revolutionary/dp/1538724618/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr=

Dr. Linda McAllister-Lucas is an NIH-funded physician-scientist who investigates how dysregulated intracellular signaling contributes to inflammatory disease and cancer. She co-directs a research laboratory with her husband Dr. Peter Lucas, a member of the faculty in the Department of Pathology. Their joint Lucas / McAllister Laboratory comprises ten scientists at varying stages of training. Learn more about Dr. McAllister's research.

First up this week, Staff Writer Adrian Cho talks with host Sarah Crespi about a fusion company that isn't aiming for net energy. Instead, it's looking to sell off the high-energy neutrons from its fusion reactors for different purposes, such as imaging machine parts and generating medical isotopes. In the long run, the company hopes to use money from these neutron-based enterprises for bigger, more energetic reactors that may someday make fusion energy. Next, we hear from Tian Du, a Ph.D. candidate in the Dr John and Anne Chong Lab for Functional Genomics at the University of Sydney. She talks about finding antivenom treatments by screening all the genes in the human genome. Her Science Translational Medicine paper focuses on a strong candidate for treating spitting cobra bites, but the technique may prove useful for many other venomous animal bites and stings, from jellyfish to spiders. This week's episode was produced with help from Podigy. About the Science Podcast Authors: Sarah Crespi, Adrian Cho Learn more about your ad choices. Visit megaphone.fm/adchoices

First up this week, Staff Writer Adrian Cho talks with host Sarah Crespi about a fusion company that isn't aiming for net energy. Instead, it's looking to sell off the high-energy neutrons from its fusion reactors for different purposes, such as imaging machine parts and generating medical isotopes. In the long run, the company hopes to use money from these neutron-based enterprises for bigger, more energetic reactors that may someday make fusion energy. Next, we hear from Tian Du, a Ph.D. candidate in the Dr John and Anne Chong Lab for Functional Genomics at the University of Sydney. She talks about finding antivenom treatments by screening all the genes in the human genome. Her Science Translational Medicine paper focuses on a strong candidate for treating spitting cobra bites, but the technique may prove useful for many other venomous animal bites and stings, from jellyfish to spiders. This week's episode was produced with help from Podigy. About the Science Podcast Authors: Sarah Crespi, Adrian Cho Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Dr. Szot, Dr. Larson, Dr. Shim, and Dr. Reist as they discuss new therapeutic agents for the treatment of Alzheimer's disease and their role in management of the disease. CME Credit Available:  https://uiowa.cloud-cme.com/course/courseoverview?P=0&EID=66930  Resources:  Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. DOI: 10.1056/NEJMoa2212948. PMID: 36449413 Lecanemab: Looking Before We Leap. Neurology. DOI: 10.1212/WNL.0000000000207505. PMID: 37479527 Host: Joseph Szot, MD Associate Dean for Continuing and Integrated Medical Education Clinical Professor of Internal Medicine University of Iowa Carver College of Medicine Guests: Scott Larson, MD Clinical Assistant Professor of Family Medicine University of Iowa Department of Family Medicine Jeff Reist, PharmD Clinical Associate Professor of Pharmacy Practice and Science Director, Pharmacy Practice Learning Center University of Iowa College of Pharmacy HyungSub Shim, MD of Neurology and Psychiatry Clinical Assistant Professor Medical Director of the Memory Disorders Clinic University of Iowa Department of Neurology and Psychiatry Financial Disclosures:  Dr. Joseph Szot, his guests and the members of the planning committee for Rounding@IOWA have no relevant financial relationships to disclose. CME Credit Designation: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 0.5 ANCC contact hour. Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.)  

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

As part of the 2024 Prostate Cancer Patient Conference, Dr. Rahul Aggarwal reviews emerging treatment approaches for advanced prostate cancer, including developments for antibody-drug conjugates, immunotherapy (T cell engagers), targeted radiation, and targeting Androgen Receptor Signaling. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 39772]

More clinical pearls from ACP #IM2024, including emerging infectious diseases in the US (malaria, dengue, super gonorrhea, and a resurgence of syphilis), new C. diff treatments, coagulopathy and cirrhosis, fatty liver disease, HFpEF, peripheral arterial disease, Lp(a) and ApoB, CAR T-cells for autoimmune disease, SGLT2i for gout, and hematology updates. Paul and Watto are joined by Drs. Nora Taranto, Beth Garbitelli, and of course Chris “The Chiu Man” Chiu. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Tropical Diseases: Resurgence of Malaria and Dengue Fever 03:44 Infectious Diseases: Syphilis Rates and New Treatments for C. diff 08:28 Coagulopathy and Cirrhosis: Managing Hemostasis and Portal Vein Thrombosis 11:34 Fatty Liver Disease: Risk Stratification and Treatment 14:59 Cardiology Updates: Cardiovascular Kidney Metabolic Syndrome 31:03 New Medications for Hypertension 32:54 Renal Denervation and Hypertension 33:51 Lp(a) Drugs and Their Potential 36:01 Peripheral Arterial Disease and Claudication 38:10 SGLT2 Inhibitors and Gout 41:50 APO-B and LDL Cholesterol 42:45 Secondary Hypogonadism and Head and Neck Radiation 45:30 VEXAS: A Genetic Autoimmune Condition 49:08 Obesity-Induced Leukocytosis 52:49 CAR T-Cell Therapy in Rheumatologic Diseases Credits Producers/Writers/Show Notes: Matthew Watto MD, FACP; Paul Williams MD, FACP, Nora Taranto MD, Chris Chiu MD, Beth Garbitelli MD CME, Cover Art: Beth Garbitelli MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Nora Taranto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Sponsor: Litter Robot Go to stopscooping.com/CURB and enter promocode CURB to save an EXTRA $50 on any Litter-Robot bundle. Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Beginly Visit beginlyhealth.com/curbsiders for the job matching platform for every Physician and Advanced Practice Clinician, from training to practice

Food allergies are a major problem – common, potentially deadly, and without effective medicines to prevent them from occurring. But earlier this year, researchers and doctors published a clinical trial reporting an effective new treatment for preventing allergic food reactions. In today's episode of Beyond the Abstract, Derek and Dan dive into the science behind the new treatment and what it might mean for the future of combating a deadly disease. Article discussedWood et al., Omalizumab for the Treatment of Multiple Food Allergies. New England Journal of Medicine. 2024 (https://www.nejm.org/doi/full/10.1056/NEJMoa2312382)The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.

Why talk to a hematologist about mast cell disease and systemic mastocytosis treatment? Dr. Douglas Tremblay, a leading hematologist, joins Dr. G and Kortney to discuss the role of a hematologist-oncologist in diagnosing and treating mastocytosis. We discuss bone marrow's vital role in diagnosing and treating systemic mastocytosis.  Dr. Tremblay discusses the latest KIT inhibitors, a promising group of medications, and explains the difference between indolent and advanced systemic mastocytosis. He clarifies how KIT inhibitors work and emphasizes the importance of managing side effects. Finally, Dr. Tremblay provides insights into the future of KIT inhibitor approval and explores the possibility of participating in a clinical trial for Bezulastinib.  What we cover in this episode about treating systemic mastocytosis: What is a hematologist looking at with mast cell disease patients? Mast cell diseases and the role of bone marrow Bone marrow biopsy for systemic mastocytosis  What is a bone marrow biopsy? Information bone marrow biopsy provides for diagnosis KIT mutation  KIT mutation testing in bone marrow and blood (digital droplet PCR) Indolent Mastocytosis versus Advanced Mastocytosis Current research for treating mast cell disease How KIT inhibitors work Do KIT inhibitors weaken the immune system? KIT Inhibitors discussed in this episode: Avapritinib Bezulastinib Elenestinib Are KIT inhibitors a cure for mast cell disease? Determining the tolerance for side effects of medications when researching and adding new medicines for diseases  The meaning of ‘NIB' in the medication names The timeline for the new KIT inhibitors approval The type of patient that can participate in the clinical trials for Bezulastinib Resources about mast cell disease: Dr. Tremblay: https://profiles.mountsinai.org/douglas-a-tremblay Dr. Tremblay's email: douglas.tremblay@mssm.edu  Mast Cell Disease Overview: https://allergyasthmanetwork.org/health-a-z/mast-cell-diseases/ What is Anaphylaxis? https://allergyasthmanetwork.org/anaphylaxis/ What is Epinephrine? https://allergyasthmanetwork.org/anaphylaxis/what-is-epinephrine/ The Mast Cell Disease Society: https://tmsforacure.org/ Current studies enrolling patients: https://tmsforacure.org/clinical-trials/

Dr. Lauren Zimski brings expert dry eye care to the Denver area. She and Dr. Amigues treat many of the same patients! Tune in to learn all about dry eye syndrome. The discussion dives into the innovative treatments provided by Dr. Zimksi, which go beyond the limited options provided by most ophthalmologists: artificial tears and punctal plugs. You'll also learn about the causes of dry eye when it comes to rheumatologic conditions. This is the first episode in a two part series.  Next week, we'll discuss in more detail the correlations between rheumatologic conditions and dry eye. As a board-certified ophthalmologist with a special interest in ocular surface disease, Dr. Zimski spent many years in private practice where she saw an increasing number of patients struggling with eye discomfort, redness and fluctuating vision. Finding that common recommendations such as artificial tears were rarely effective, Dr. Zimski decided to seek out better solutions through research studies, conferences, and engaging thought leaders in the ocular surface disease space. With various treatment options available in the market, she wanted to bring the best new technology into her practice and to integrate it in a stepwise approach to achieve the best results for her patients. You can find lauren at https://www.laurenzimskimd.com, and be sure to give her a follow on social media for dry eye tips and insights:Instagram: @lauren_zimskimdFacebook: dryeyedenverEpisode Content ____________________________________________________--- 00:01 - Introduction--- 00:26 - Introducing Dr. Lauren Zimski--- 01:11 - Dr. Zimski's Journey into Ophthalmology and Dry Eyes--- 02:17 - Concerns about Younger Patients with Severe Dry Eye--- 03:40 - Definition of Dry Eyes in Ophthalmology--- 04:50 - Approach to Diagnosing Dry Eyes--- 06:40 - Connection Between Dry Eyes and Skin Conditions--- 08:44 - Treatment of Dry Eyes: Dermatologist's Involvement--- 09:12 - Traditional Treatments: Artificial Tears and Lacrimal Plugs--- 10:00 - New Tools and Imaging Systems in Diagnosis--- 11:00 - Importance of Evaluating Eyelid Conditions and a Thorough Diagnostics Process--- 15:12 - Stepwise Treatment Process for Dry Eyes--- 15:40 - Inflammadry Test--- 16:37 - Explanation of Puctal Plugs--- 18:00 - IPL (Intense Pulse Light Therapy) for Dry Eyes--- 21:25 - Fish Oil and Other Home Care Regimens--- 26:06 - Hope for Patients and New Treatments in Dry Eye Care--- 28:38 - How to Contact Dr. Lauren Zimski____________________________________________________________________Learn more about Rheumatology on Dr. Amigues' education focused channel, @Rheumatology101  And give us a follow on social media! We greatly appreciate your support. https://www.instagram.com/unabridgedmd/https://www.facebook.com/UnabridgedMDhttps://www.tiktok.com/@unabridgedmdAre you, or someone you love, looking for a rheumatologist near you? Maybe you queried Google for the “best rheumatologist in Denver” and felt that no other arthritis clinic in Denver really seemed personable? Or maybe you are simply looking for a doctor who will listen to you and work with you to achieve disease remission? Well, you have come to the right place. UnabridgedMD has the best rheumatologist in Denver, Colorado and we cannot wait to work with you.Click here to get in touch: https://www.unabridgedmd.com Or give us a call: 303-731-4006#rheumatologist #unabridgedmd #dryeyesyndrome #denver #drIf you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!

Today's podcast guest is the remarkable Doctor Cudkowicz, a neurologist and neuroscientist renowned for her work on amyotrophic lateral sclerosis (ALS). A Julieanne Dorn Professor of Neurology at Harvard Medical School and director of the Sean Healey ALS clinic at Massachusetts General Hospital, Merit has been pivotal in leading collaborative research and clinical trials for ALS. With an impressive academic journey from MIT to Harvard, her passion for neuroscience and patient care is evident. Merit's work brings hope to countless individuals affected by this condition. Get ready to be inspired by her groundbreaking contributions and insights into the world of neurology and neuroscience!   Tim Green's "Nothing Left Unsaid" is a weekly podcast hosted by Tim and Troy Green. Tim is a former first round NFL draft pick, member of the College Football Hall of Fame, New York Times #1 Bestselling Author, former Fox broadcaster, NPR contributor, family man, ALS advocate, and so much more. Each week, Tim and Troy will sit down with interesting people to have thoughtful conversations. The guests will range from celebrities, athletes, academics, doctors, authors, and more. As Tim battles his ALS diagnosis, nothing is out of bounds and there will be nothing left unsaid. #NothingLeftUnsaid #TimGreen #podcast   SPONSORS  ElevenLabs: Thanks to ElevenLabs (https://elevenlabs.io/) for supporting this episode and powering Tim's voice.  Barclay Damon: Thank you to my law firm, for supporting this episode (https://www.barclaydamon.com/).    SOCIAL Twitter: https://twitter.com/nlutimgreen  Facebook: https://www.facebook.com/TGNothingLeftUnsaid  Instagram: https://www.instagram.com/tgnlu/  TikTok: https://www.tiktok.com/@tgnothingleftunsaid    AUDIO ONLY  Spotify: https://open.spotify.com/show/5fhcANt7CSnYvgBlgxpVVa  Apple Podcasts:https://podcasts.apple.com/us/podcast/nothing-left-unsaid/id1734094890    PERSONAL  Tackle ALS: https://www.tackleals.com/ Tim Green Books: https://authortimgreen.com/

200 million women worldwide battle endometriosis, a condition with no cure and limited treatment options for decades – until now. Discover the latest breakthroughs in treatment and womb transplant successes in today's episode.  Subscribe to podcast updates: https://form.jotform.com/223614751580152 Ask Ric: https://www.thetayf.com/pages/ask-ric ----- Follow Ric on social media: Facebook: https://www.facebook.com/RicEdelman Instagram: https://www.instagram.com/ric_edelman/ LinkedIn: https://www.linkedin.com/in/ricedelman/ X: https://twitter.com/ricedelman YouTube: https://www.youtube.com/@RicEdelman ----- Brought to you by: Invesco QQQ: https://www.invesco.com/qqq-etf/en/home.html Schwab: https://www.schwab.com/ Bitwise: https://www.bitwise.com Disclosure page: https://www.thetayf.com/pages/sponsorship-disclosure-fee -----

As researchers push to find a cure for Alzheimer's disease, there are lots of new and exciting discoveries and drug approvals being made. We enlisted Dr. Parichita Choudhury, a cognitive neurologist at Banner Sun Health Research Institute, to answer some of our most-requested questions about what all of this means. She untangles the latest drug trial results, what the names of these drugs mean, and how healthcare systems implement the use of these breakthrough treatments. 

In this episode, I have the pleasure of sitting down with Dr. Troy Spurrill to delve into the complexities of Lyme disease and mold toxicity. We explore their causes, symptoms, and treatments, and I emphasize the holistic nature of health, which includes emotional, physical, mental, and spiritual aspects. Dr. Spurrill shares an inspiring story of one of his patients, highlighting the incredible power of mindset in the healing process. We also touch on the spiritual aspects of health, discussing the importance of forgiveness and vulnerability. Throughout our conversation, we underscore the interconnectedness of emotional well-being and physical health.Chapters(00:00) Podcast Introduction(02:22) Guest Introduction(04:39) Discussion on Lyme Disease(07:51) Increase in Lyme Disease Cases(10:33) Symptoms of Lyme Disease(13:26) Impact of Lifestyle and Emotional Well-being(16:58) Forgiveness and Healing(19:09) The Mind of Christ(20:22) Receiving God's Love and Healing(24:13) New Treatments for Lyme disease(27:04) Mold Toxicity and its Effects(30:51) Addressing Emotional Health in Healthcare(34:42) Emotional and Physical Healing(35:36) Closing Remarks and PrayerResources mentioned:Synapse Website Green DrinkConnect with today's guest:InstagramFacebookDr. Troy Spurrill is the CEO and founder of Synapse: A Center For Health and Healing. He received a Bachelor of Science in Molecular Biology from the University of Manitoba and a Doctor of Chiropractic from Northwestern Health Sciences University, and has extensive training in Functional Neurology, Functional medicine, Nutrition, and Applied Kinesiology.Dr. Spurrill travels extensively conducting seminars on the subjects of disease prevention and healing through a faith-filled healthy lifestyle. He has authored the book Formula For Life and is credited with the development of a brain-body technique to reverse the cycles of post-traumatic stress disorder and cumulative stress syndromes. Dr. Spurrill's next book will be coming out later this year.His mission is to impact the well-being of people around the world by providing solutions to complicated life issues, and to create sanctuaries that promote the restoration and perpetuation of health, happiness, and prosperity! Dr. Spurrill's company can be found in Eagan, Minnesota.P.S. If you're just checking out the show to see if it's a good fit for you, welcome!If you're really serious about becoming Visibly Fit, you'll get the best experience if you download the worksheets available at https://wendiepett.com/visiblyfitpodcast.

Akrivia Health provides research data, clinical trial optimization, and molecular characterization for mental health and dementia. We speak with David Newton, COO & Co-Founder of Akrivia Health, about how they use AI to process free text notes into structured data, all while safeguarding patient privacy.

Last week, the Food and Drug Administration approved two new gene therapies to treat sickle cell disease. Roughly 100,000 people in the U.S. live with the debilitating and painful blood disorder, most of whom are African American. One of these “milestone treatments'' is a drug using powerful gene-editing technology never before approved for human use. It can repair a mutation that produces sickle-shaped red blood cells that can lead to stroke, organ damage and premature death.  But the millions of dollars the treatments cost is just one of the barriers facing patients like Jayla Eddins, a high school senior in Salem, and her mother, Jamie Eddins, who helps manage her daughter’s illness. Dr. Trisha Wong is an associate professor of pediatrics in the division of hematology and oncology at Oregon Health & Science University. They join us to talk about the physical and emotional toll of the disease as new breakthroughs emerge to treat it. 

A new hope for patients with Duchenne Muscular Dystrophy. Do rodents have the key to immortality? Buying a dog could be great for your health. Learn More: https://radiohealthjournal.org/medical-notes-rodents-may-be-the-key-to-immortality-new-treatments-for-muscular-dystrophy-and-why-dogs-are-great-for-your-health/ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Ep. 73 - New treatments for arthritic pets - Show NotesOur pets can suffer from arthritis, just like their human owners. For years, the only treatment has been non-steroidal anti-inflammatory drugs (NSAIDS.) However, two drugs have recently been approved by the FDA for our pets.Dr. Tamara Grubb returns to the podcast to explain how these new drugs, utilizing the science of monoclonal antibodies, are revolutionizing the treatment of osteoarthritis for our pets.Here are links to information we talked about today:Listen to Dr. Tamara Grubb's first visit to The Family Pet Podcast in Episode 35This explainer from the Cleveland Clinic explains monoclonal antibodies in human medicine and is a good insight into what the future might hold for pet medicineDog owners can learn about LibrelaCat owners can learn about SolensiaZoetis announced the U.S. commercial launch of Librela (bedinvetmab injection), which the company says is the first and only anti-NGF monoclonal antibody treatment to control canine osteoarthritis pain. The product in May received approval from the FDA. Got a question for Michael and Stephen? Run across something interesting you want to share with the show? Do you have a topic idea for a future episode? Send it to us at thefamilypetpodcast@gmail.com. 

The National Security Hour with LTC Sargis Sangari USA (Ret.) – Dr. Robert Beckman, C-Founder, Executive Director of TreatNOW.org, and Chief Knowledge Officer at the Foundation for the Study of Inflammatory Disease (foundsid.org), joins me to discuss the lingering effects of Traumatic Brain Injury (TBI) & Post-traumatic stress disorder (PTSD) and the means and the multiple ways of new treatments to address them.

Here we go! Mental is the brain-child of Bobby Temps, who lives and thrives while managing his own mental health. Each Thursday we delve into a factor or condition that affects the mind and how to better manage it. Join our Subscription on Apple Podcasts for extended ad free episodes… We have a very blue website with loads of great resources HERE

Brighter Days Ahead: Leaving Depression Behind Through Innovative New Treatments by Theodore A. Henderson Neuro-luminance.com Depression is not what you think it is. Yes, it is a downward spiral of misery, self-doubt, angst, and apathy, but the cause is not a personality failing or a lack of serotonin. Have medications designed to change serotonin or dopamine levels in your brain helped you? Depression does, indeed, result from changes in your brain, but the nature of these transformations will shock and surprise you. This life-changing book will help you see depression in a new light…leading you to powerfully effective treatments. Psychiatrist, brain scientist, and inventor, Dr. Theodore Henderson paints a real-world picture of depression with moving stories and full color illustrations that makes the science underlying this common mental health condition come to life. Drawing upon almost two decades of intensive personalized treatment of hundreds of patients, Dr. Henderson deftly combines brain science with evocative case histories to explains exactly how the brain changes as a result of depression and how less well-known contemporary treatments for it work to reverse these changes. Gone are the chemical imbalance theories. Gone are the pull-yourself-up-by-the-bootstraps admonishments. Using the example of the powerful antidepressant effects of ketamine infusion therapy as a window into understanding not only what depression does to the brain, but how neuroplasticity can reverse it, often permanently, Dr. Henderson offers the reader even more information about this complex condition. He introduces other novel and powerful treatments for depression, as well as addressing childhood trauma, brain injury, inflammation, and the importance of mindfulness. In this deeply informed book, Dr. Henderson guides the reader to understanding the brain, depression, and effective solutions in a sometimes poignant, sometimes gritty, no-holds barred, real-world look at depression and recovery. About the Author Theodore A. Henderson MD, PhD is a descendent of Algonquin, French and English ancestors. He is president and founder of both The Synaptic Space and Dr. Theodore Henderson, Inc., clinical service firms. He is Co-Founder of Neuro-Luminance Inc, which is bringing revolutionary treatments to bear upon traumatic brain injury, depression, Alzheimer's disease, post-COVID fatigue syndrome, and other brain disorders. He is also the co-founder of the Neuro-Laser Foundation, a non-profit research foundation. He holds two patents and three patents-pending. Dr. Henderson is president of the International Society of Applied Neuroimaging. He has published in neuroimaging, psychopharmacology, dementia, photobiomodulation, and traumatic brain injury. He has over 70 publications and has been cited in over 900 scientific papers. He is editor or guest editor for numerous journals, including Frontiers in Psychiatry, JAMA Psychiatry, and PLoSOne. The work of he and his colleagues on using SPECT brain scans to differentiate brain injury from PTSD was recently recognized as a “Top Science Story” by Discover Magazine for 2015. A philanthropist himself, Dr. Henderson is also a father of two, stepfather of two and grandfather of three.

Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023CLLReview/InterviewAudio)

Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia

In this episode of Causes or Cures, Dr. Eeks chats with Dr. Ari Green about the latest thinking on what causes Multiple Sclerosis (MS) and who it impacts most, current treatment approaches, and research on potential new treatments involving remylenation therapies. He chats about the ReBUILD trial and something called the "Myelin Water Fraction" and how it can be used to measure remylenation. He also discusses the latest evidence on preventive factors for MS. Dr. Green is a neurologist and neuro-ophthalmologist and medical director of the UCSF Multiple Sclerosis Center. He is also director of the UCSF Neurodiagnostic Center. His research focus is on reparative treatments for people with MS and slowing down neurodegeneration. You can learn more about him here. You can contact Dr. Eeks at bloomingwellness.com.Follow Dr. Eeks on Instagram here.Or Facebook here.Or Twitter.Or Threads.Subcribe to her newsletter here!Support the show

Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023GE/AudioInterview)

Featuring perspectives from Ms Kristen B Battiato and Dr Jennifer Woyach, including the following topics: Introduction (0:00) Case: A woman in her early 70s responding to ibrutinib for 4 years (27:07) Case: A woman in her early 80s with TP53-mutant, del(17p) disease responding to acalabrutinib (38:02) Case: A man in his mid 50s with chronic lymphocytic leukemia/small lymphocytic leukemia treated for a year with obinutuzumab followed by venetoclax; no evidence of disease for 3 years (43:29) Case: A Cuban woman in her mid 60s with multiregimen-recurrent disease, now receiving venetoclax (53:17) NCPD information and select publications

Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer. CME information and select publications here (https://www.researchtopractice.com/ONS2023Bladder/Audiointerview)

This week, we discuss how to know when it's time to take a break or move on to new treatments when you're trying to conceive. Share your thoughts with us! ⁠⁠Use this link⁠⁠ to submit your questions and comments. Every submission is an entry into our monthly giveaway! Join the ⁠⁠⁠⁠⁠Facebook Group⁠⁠⁠⁠⁠  Abbie's Instagram: ⁠⁠⁠⁠@abbiegclark⁠⁠⁠⁠  Haley's Instagram: ⁠⁠⁠⁠@haley.rianne⁠⁠⁠⁠  Email: insidethejourneypod@gmail.com ⁠⁠⁠⁠www.insidethejourney.com⁠⁠⁠⁠⁠ 

Featuring perspectives from Dr Kristen K Ciombor and Mrs Amanda K Wagner, including the following topics: Introduction (0:00) Colorectal Cancer (10:18) Gastroesophageal Cancers (39:21) NCPD information and select publications

On this summer episode, we discuss some of the latest news topic on the docket! Information about new treatments for Erectile dysfunction recently announced that has many people intrigued. New data on Testosterone replacement in men. Maybe its safer than initially thought? New data on hysterectomies performed on women younger than 50 may lead to concerning side effects. We discuss these topics and many more on this weeks episode of the Health and Wellness Connection. Donate to the show via cash app via $drbarryhealth.

Ian Sample speaks to the Guardian's health editor, Andrew Gregory, and Dr Roy Herbst about the world's biggest annual gathering of oncology professionals. Each year's event features a mass of new research, and 2023 was no exception. What were the standout advances, and could they lead to permanent changes in the way we treat, think about and live with cancer?. Help support our independent journalism at theguardian.com/sciencepod

Holistic veterinarian Dr. Rose DiLeva owns the Animal Wellness Center veterinary practice in Chadds Ford, PA, where the goal is to provide clients and their animal companions with the best in holistic veterinary medicine, while integrating conventional veterinary medicine when needed.

IN THIS EPISODE OF THE HUMAN UPGRADE™… Vincent Pedre, M.D., explains how consuming too much sugar can lead to insulin resistance and diabetes by causing shifts in the microbiome that reduce insulin signaling. He also highlights how omega-6 fats found in processed foods contribute to inflammation and chronic disease by carrying lipopolysaccharide toxins through cell membranes. For over a decade, board-certified internist and Functional Medicine certified practitioner, Dr. Pedre, founder of Happy Gut Life, has helped people improve their well-being and quality of life by building the foundation of gut health that supports total physical and mental wellness. He believes that healing begins in the kitchen through the foods we eat. He brings together years of research and clinical experience to offer you real solutions in his newest book, “The GutSMART Protocol: Revitalize Your Health, Boost Your Energy, and Lose Weight in Just 14 Days with Your Personalized Gut-Healing Plan.”The balance between good and bad bacteria is both important and nuanced—more microbial diversity in the gut is not always better. "The focus should be on metabolomics, not just diversity when it comes to gut bacteria,” Dr. Pedre says. Another focus includes gut interrelationships and the seven big systems in your body affected by leaky gut: skin, airway, brain, joints, energy, metabolism, and immune system.Watch this episode on YouTube!Find all the links and resources in the show notes.WE APPRECIATE OUR PARTNERS. CHECK THEM OUT! Anti-aging Powerhouse: https://spermidinelife.us/dave , use code DAVE25 to save 25% on your first purchaseMust-Have Magnesium: https://magbreakthrough.com/dave, use code DAVE10 to get a 10% discountDave Asprey's NEW Book! “Smarter Not Harder: The Biohacker's Guide to Getting the Body and Mind You Want” is out now. https://daveasprey.com/books/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.